<DOC>
	<DOCNO>NCT02486640</DOCNO>
	<brief_summary>This study aim evaluate potential predictor adherence investigate representative cohort MS patient Germany treat Betaferon</brief_summary>
	<brief_title>Evaluation Potential Predictors Adherence Investigating Representative Cohort Multiple Sclerosis ( MS ) Patients Germany Treated With Betaferon</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients diagnosis relapse remit multiple sclerosis clinically isolated syndrome . Patients must treatment Betaferon decision treat patient Betaferon make attend physician . Patients must use BETACONNECTTM autoinjector Betaferon application . Written informed consent must obtain . Patients receive disease modify drug . Contraindications Betaferon describe Summary Product Characteristics . Patients participate clinical noninterventional study , evaluate MS therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RRMS , CIS</keyword>
</DOC>